Back to Search Start Over

Therapeutic requirements in active ulcerative proctitis: A single-centre study

Authors :
Míriam Mañosa
Eduard Cabré
M Calafat
Macarena Larraín
Eugeni Domènech
Triana Lobatón
Laura Marín
Noemí Caballero
Source :
Gastroenterologia y Hepatologia, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Publication Year :
2017
Publisher :
Elsevier BV, 2017.

Abstract

Background: Ulcerative proctitis (UP) presents distinctive clinical characteristics, outcomes and therapeutic approaches as compared to left-sided and extensive ulcerative colitis (UC). Aim: To describe the current therapeutic requirements and clinical outcomes in patients with active UP. Methods: Retrospective observational study conducted in a referral IBD centre. Patients with UP in follow-up between 1989 and 2014 were included. The clinical characteristics, as well as the different treatments and drug formulations administered to treat flares, were recorded. Results: Out of 687 UC patients, 101 patients (15%) with UP were included. Median follow-up was 8 years (IQR 3-14) and 49% of patients presented disease activity during the study period. Topical mesalazine monotherapy (90%) was the most commonly administered treatment for disease activity (mostly as suppositories), followed by topical steroids (47%) and oral mesalazine (56%) in monotherapy or combination therapy. Only 14% and 16% of patients required oral prednisone and beclomethasone, respectively. Conclusions: In clinical practice, active UP presents mostly favourable outcomes. Mesalazine suppositories are by far the most used treatment for these patients. (C) 2017 Elsevier Espana, S.L.U., AEEH y AEG. All rights reserved.

Details

ISSN :
24443824 and 02105705
Volume :
40
Database :
OpenAIRE
Journal :
Gastroenterología y Hepatología (English Edition)
Accession number :
edsair.doi.dedup.....00f83cc9e906132bda30b26be058ad13
Full Text :
https://doi.org/10.1016/j.gastre.2017.05.009